인트론바이오

048530KOSDAQ기초 의약물질 제조업

57.8 / 100

Reference Date: 2026-07-24

Financial Score19.5 / 40

News Sentiment21.3 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

IntronBio focuses on developing biopharmaceuticals based on bacteriophage technology and molecular diagnostic solutions. The company's drug development division targets antibiotic-resistant bacterial infections and immune therapies, while its diagnostic division produces molecular test kits, including COVID-19 diagnostic products, contributing to revenue.

Number of Employees

77people

Average Salary

64.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 25.444.0Point

PBR

1.11Industry Average 1.264.0Point

In line with industry avg

ROE

-11.66Industry Average -6.033.5Point

1.9x industry avg (good)

Debt Ratio

0.52Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼21.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼55.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -8.0% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
인트론바이오, ESMO서 대장암 연구 공개…"플랫폼 경쟁력 뽐낸다"
인트론바이오의 ESMO 발표로 대장암 치료 플랫폼 IMPA의 경쟁력이 강조되어 긍정적인 시장 반응 예상.
Positive
박장준 인트론바이오 연구소장 "차세대 SC 기술로 알테오젠 잡겠다"
인트론바이오가 혁신적인 SC 기술 개발로 경쟁 우위 확보를 선언하며 긍정적인 시장 반응 예상.
Positive
인트론바이오, '리픽싱 無' 30억 CB 발행…"전략적 가치투자 유치"
인트론바이오의 CB 발행으로 전략적 가치투자 유치 성공, 기업 가치 상승 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 2,510Won52-week high 6,65052-week low 2,330

1-month return3.0Point

1m -0.2% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-21
Neutral증권발행결과(자율공시)2026-07-15
Neutral주식등의대량보유상황보고서(일반)2026-07-03
Neutral주요사항보고서(전환사채권발행결정)2026-06-30